Newer trends in the management of psoriasis at difficult to treat locations: Scalp, palmoplantar disease and nails

Indian Journal of Dermatology, Venereology and Leprology

Volumn 76, Issue 6, 2010, Pages 634-644

  Handa, Sanjeev ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Management; nails; palmoplantar; psoriasis; scalp

Indexed keywords

ALEFACEPT; AMINOLEVULINIC ACID; AZATHIOPRINE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE PLUS CALCIPOTRIENE; BETAMETHASONE VALERATE; CALCIPOTRIOL; CLOBETASOL PROPIONATE; CLOBEX; COAL TAR; CYCLOSPORIN; DITHRANOL; EFALIZUMAB; ETANERCEPT; ETRETIN; HYDROXYUREA; KETOCONAZOLE; LEFLUNOMIDE; LUXIQ; METHOTREXATE; METHOXSALEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYTAR; PSORALEN; PYRITHIONE ZINC; SALAZOSULFAPYRIDINE; SALICYLIC ACID; SELENIUM; SHAMPOO; SULFUR; TACROLIMUS; TAZAROTENE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BURNING SENSATION; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CREAM; DISEASE SEVERITY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG RESPONSE; DRY SKIN; EXCIMER LASER; FOAM; HUMAN; HYDROGEL; HYPERTENSION; KIDNEY FUNCTION; NAIL DISEASE; NAUSEA; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOTHERAPY; POMADE; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; PUSTULOSIS PALMOPLANTARIS; PUVA; SCALP; SIDE EFFECT; SINGLE DRUG DOSE; SKIN IRRITATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, TOPICAL; ANIMALS; DERMATOLOGIC AGENTS; DISEASE MANAGEMENT; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; NAIL DISEASES; PHOTOTHERAPY; PSORIASIS; SCALP DERMATOSES;

EID: 78649271458     PISSN: 03786323     EISSN: 09733922     Source Type: Journal    
DOI: 10.4103/0378-6323.72455     Document Type: Conference Paper

References (122)

1. Kaur I, Handa S, Kumar B. Natural history of psoriasis: a study from the Indian subcontinent. J Dermatol 1997;24:230-4.
2. van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol 2001;2:159-65.
3. Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin Dermatol 2008;26:448-59.
4. Farber EM, Nall L. Natural history and treatment of scalp psoriasis. Cutis 1992;49:396-400.
5. van de Kerkhof PC, de Hoop D, de Korte J, Kuipers M V. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 1998;197:326-34.
6. Chan CS, Van Voorhees AS, Lebwohl MG, Korman NJ, Young M, Bebo Jr B F, et al. Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009;60:962-71.
7. Papp K, Berth-Jones J, Kragballe K, de la Brasinne M. Scalp psoriasis: A review of current topical treatment options. J Eur Acad Dermatol Venereol 2007;21:1151-60.
8. nd ed. London: Informa Healthcare; 2009.
9. Chen SC, Yeung J, Vhren MM. Scalpdex: A quality of-life instrument for scalp dermatitis. Arch Dermatol 2002;138:803-7.
10. Reid DC, Kimball AB. Clobetasol propionate foam in the treatment of psoriasis. Expert Opin Pharmacother 2005;6:1735-40.
11. Mazzotta A, Esposito M, Carboni I, Schipani C, Climenti S. Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis. J Derm Treat 2007;18:84-7.
12. Olsen EA, Cram DL, Ellis CN, Hickman JG, Jacobson C, Jenkins EE, et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 1991;24:443-7.
13. Katz HI, Lindholm JS, Weiss JS, Shavin JS, Morman M, Bressinck R, et al. Efficacy and safety of twice daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis. Clin Ther 1995;17:390-401.
14. Jarratt M, Breneman D, Gottlieb AB, Poulin Y, Liu Y, Foley V. Clobetasol propionate shampoo 0.05%: A new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol 2004;3:367-73.
15. Hogan DJ, Rooney ME. Facial telangiectasia associated with long-term application of a topical corticosteroid to the scalp. J Am Acad Dermatol 1989;20:1129-30.
16. Feldman SR, Sangha N, Setaluri V. Topical corticosteroid in foam vehicle offers comparable coverage compared with traditional vehicles. J Am Acad Dermatol 2000;42:1017-20.
17. Franz TJ, Parsell DA, Myers JA, Hannigan J F. Clobetasol propionate foam 0.05%: A novel vehicle with enhanced delivery. Int J Dermatol 2000;39:535-9.
18. Stein L. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis. J Am Acad Dermatol 2005;53: S39-49.
19. Feldman SR, Housman TS. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol 2003;4:221-4.
20. Johnson LA. P. O. W. E. R. (providing outcomes with effective results) in the shower-A patient experience program examining scalp psoriasis treatments. J Am Acad Dermatol 2007;56: AB188.
21. Green C, Ganpule M, Harris D, Kavanagh G, Kennedy C, Mallett R, et al. Comparative effects of calcipotriol (MC 903) solution and placebo (vehicle of MC 903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994;130:483-7.
22. Thaci D, Daiber W, Boehncke WH, Kaufmann R. Calcipotriol solution for the treatment of scalp psoriasis: Evaluation of efficacy, safety and acceptance in 3, 396 patients. Dermatology 2001;203:153-6.
23. Barnes L, Altmeyer P, Forstrom L, Stenstrom MH. Long-term treatment of psoriasis with calipotriol scalp solution and cream. Eur J Dermatol 2000;10:199-204.
24. Shah MK. Coconut oil compound ointment. Indian J Dermatol Venereol Leprol 2003;69:303-4.
25. Kaur I, Saraswat A, Kumar B. A comparison of three therapeutic modalities in scalp psoriasis and a review of literature. Indian J Dermatol 2003;48:22-6.
26. Paghdal KV, Schwartz RA. Topical tar: Back to the future. J Am Acad Dermatol 2009;61:294-302.
27. Langner A, Wolska H, Hebborn P. Treatment of psoriasis of the scalp with coal tar gel and shampoo preparations. Cutis 1983;32:290-1, 295-6.
28. Griffiths CE, Finlay AY, Fleming CJ, Barker JN, Mizzi F, Arsonnaud S. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. J Dermatolog Treat 2006;17:90-5.
29. Lebwohl MG, Breneman DL, Goffe BS, Grossman JR, Ling MR, Milbauer J, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998;39:590-6.
30. van der Vleuten CJ, van de Kerkhof PC. Management of scalp psoriasis: guidelines for corticosteroid use in combination treatment. Drugs 2001;61:1593-8.
31. Jemec GB, Ganslandt C, Ortonne J P, Poulin Y, Burden AD, de Unamuno P, et al. A new scalp formulation of Calcipotriene plus Betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: A randomized, double-blind, controlled trial. J Am Acad Dermatol 2008;59:455-63.
32. Cassano N, Vena GA. Treatment of scalp psoriasis with betamethasone dipropionate and calcipotriol two-compound product. Acta Derm Venereol 2007;87:85-6.
33. Downs AM. Dovobet ointment under occlusion overnight for troublesome scalp psoriasis. Acta Derm Venereol 2006;86:57-8.
34. Buckley C, Hoffmann V, Shapiro J, Saari S, Cambazard F, Milsgaard M. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology 2008;217:107-13.
35. Rama Sastry C V, Kar PK. A study of psoralen photochemotherapy with topical tar in the management of psoriasis vulgaris. Indian J Dermatol Venereol Leprol 2001;67:305-8.
36. Kar PK, Rama Sastry C V. A study on combination therapy with PUVASOL and topical corticosteroid in psoriasis vulgaris involving scalp. Indian J Dermatol 2000;45:130-5.
37. Taneja A, Racette A, Gourgouliatos Z, Taylor CR. Broad-band UVB fiber-optic comb for the treatment of scalp psoriasis: a pilot study. Int J Dermatol 2004;43:462-7.
38. Morison WL, Atkinson D F, Werthman L. Effective treatment of scalp psoriasis using the excimer (308 nm) laser. Photodermatol Photoimmunol Photomed 2006;22:181-3.
39. Mysore V. Targeted phototherapy. Indian J Dermatol Venereol Leprol 2009;75:119-25.
40. Gattu S, Rashid RM, Wu JJ. 308-nm excimer laser in psoriasis vulgaris, scalp psoriasis, and palmoplantar psoriasis. J Eur Acad Dermatol Venereol 2009;23:36-41.
41. Krell J, Nelson C, Spencer L, Miller S. An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis. J Am Acad Dermatol 2008;58:609-16.
42. Shemer A, Nathansohn N, Kaplan B, Weiss G, Newman N, Trau H. Treatment of scalp seborrheic dermatitis and psoriasis with an ointment of 40% urea and 1% bifonazole. Int J Dermatol 2000;39:532-34.
43. Farber EM, Nall L. Nonpustular palmoplantar psoriasis. Cutis 1992;50:407-10.
44. Kumar B, Saraswat A, Kaur I. Palmoplantar lesions in psoriasis: a study of 3065 patients. Acta Derm Venereol 2002;82:192-5.
45. Farley E, Masrour S, McKey J, Menter A. Palmoplantar psoriasis: A phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol 2009;60:1024-31.
46. Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: Implications for clinical practice. J Am Acad Dermatol 2003;49:271-5.
47. Michaelsson G, Gustafsson K, Hagforsen E. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. J Am Acad Dermatol 2006;54:737-8.
48. Ono T, Jono M, Kito M, Tomoda T, Kageshita T, Egawa K, et al. Evaluation of tonsillectomy as a treatment for pustulosis palmaris et plantaris. Acta Otolaryngol 1983;401:12-6.
49. Hallberg D, Molin L. Remission of pustulosis palmaris et plantaris after intestinal shunt operation: reports on three cases. Acta Derm Venereol 1974;54:155-6.
50. Marsland AM, Chalmers RJ, Hollis S, Leonardi-Bee J, Griffiths CE. Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev 2006;25: CD001433.
51. Marsland AM, Griffiths CE. Treatments for chronic palmoplantar pustular psoriasis. Skin Therapy Lett 2001;6:3-5.
52. Lin A, Moses K. Tar revisited. Int J Dermatol 1985;24:216-8.
53. Goodfield M, Kownacki S, Berth-Jones J. Double-blind, randomized, multicenter, parallel group study comparing 1% coal tar preparation (Exorex) with a 5% coal tar preparation (Alphosyl) in chronic plaque psoriasis. J Dermatolog Treat 2004;15:14-22.
54. Finlay AY, Young DW. Short contact crude coal tar therapy for psoriasis. Clin Exp Dermatol 1985;10:371-4.
55. nd ed. New York: Informa Healthcare; 2009. p. 23-39.
56. Feldman SR, Horn EJ, Balkrishnan R, Basra MK, Finlay AY McCoy D, et al. Psoriasis: Improving adherence to topical therapy. J Am Acad Dermatol 2008;59:1009-16.
57. Duweb GA, Abuzariba O, Rahim M, al-Taweel M, al-Alem S, Abdulla SA. Occlusive versus nonocclusive calcipotriol ointment treatment for palmoplantar psoriasis. Int J Tissue React 2001;23:59-62.
58. Pearce DJ, Stealey KH, Balkrishnan R, Fleischer AB Jr, Feldman SR. Psoriasis treatment in the United States at the end of the 20th century. Int J Dermatol 2006;45:370-4.
59. Lebwohl M, Siskin SB, Epinette W, Breneman D, Funicella T, Kalb R, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996;35:268-9.
60. Menter A, Abramovits W, Colón LE, Johnson LA, Gottschalk RW. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. J Drugs Dermatol 2009;8:52-7.
61. Van de Kerkhof PC. Dithranol treatment for psoriasis: after 75 years still going strong. Eur J Dermatol 1992;1:79-88.
62. Shore RN. Clearing of psoriatic lesions after the application of tape. N Engl J Med 1985;312:246.
63. Friedman SJ. Management of psoriasis vulgaris with a hydrocolloid occlusive dressing. Arch Dermatol 1987;123:1046-52.
64. nd ed. New York: Informa Healthcare; 2009. p. 165-82.
65. Hofer A, Fink-Puches R, Kerl H, Quehenberger F, Wolf P. Paired comparison of bathwater versus oral delivery of 8-methoxypsoralen in psoralen plus ultraviolet: A therapy for chronic palmoplantar psoriasis. Photodermatol Photoimmunol Photomed 2006;22:1-5.
66. Coleman WR, Lowe NJ, David M, Halder RM. Palmoplantar psoriasis: experience with 8-methoxypsoralen soaks plus ultraviolet A with the use of a high-output metal halide device. J Am Acad Dermatol 1989;20:1078-82.
67. Sezer E, Erbil AH, Kurumlu Z, Tastan HB, Etikan I. Comparison of the efficacy of local narrowband ultraviolet B (NB-UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for palmoplantar psoriasis. J Dermatol 2007;34:435-40.
68. Kim JY, Kang HY, Lee ES, Kim YC. Topical 5-aminolaevulinic acid photodynamic therapy for intractable palmoplantar psoriasis. J Dermatol 2007;34:37-40.
69. nd ed. New York: Marcel Dekker; 2003. p. 1-29.
70. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009;60:824-37.
71. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-85.
72. Lassus A, Geiger JM. Acitretin and etretinate in the treatment of palmoplantar pustulosis: A double-blind comparative trial. Br J Dermatol 1988;119:755-9.
73. Aydogan K, Karadogan SK, Tunali S. Acitretin-induced subungual hemorrhage. Int J Dermatol 2007;46:494-5.
74. Schroder K, Zaun H, Holzmann H, Altmeyer P, el-Gammal S. Pustulosis palmo-plantaris: clinical and histological changes during etretin (acitretin) therapy. Acta Derm Venereol 1989;146:111-6.
75. Ettler K, Richards B. Acitretin therapy for palmoplantar pustulosis combined with UVA and topical 8-MOP. Int J Dermatol 2001;40:541-2.
76. Han L, Somani AK, Huang Q, Fang X, Jin Y, Xiang LH, et al. Evaluation of 308-nm monochromatic excimer light in the treatment of psoriasis vulgaris and palmoplantar psoriasis. Photodermatol Photoimmunol Photomed 2008;24:231-6.
77. Nisticò S P, Saraceno R, Stefanescu S, Chimenti S. A 308-nm monochromatic excimer light in the treatment of palmoplantar psoriasis. J Eur Acad Dermatol Venereol 2006;20:523-6.
78. Sumila M, Notter M, Itin P, Bodis S, Gruber G. Long-term results of radiotherapy in patients with chronic palmo-plantar eczema or psoriasis. Strahlenther Onkol 2008;184:218-23.
79. Myers W, Christiansen L, Gottlieb AB. Treatment of palmoplantar psoriasis with intramuscular alefacept. J Am Acad Dermatol 2005;53:127-9.
80. Guenther LC. Alefacept is safe and efficacious in the treatment of palmar plantar pustulosis. J Cutan Med Surg 2007;11:202-5.
81. Jacobi A, Schuler G, Hertl M. Differential clinical response to alefacept in combination with methotrexate in two patients with refractory palmar psoriasis. Br J Dermatol 2007;156:178-80.
82. Bissonnette R, Poulin Y, Bolduc C, Maari C, Provost N, Syrotuik J, et al. Etanercept in the treatment of palmoplantar pustulosis. J Drugs Dermatol 2008;7:940-6.
83. Stinco G, Piccirillo F, Patrone P. Treatment of palmoplantar pustular psoriasis with efalizumab: A quick response with early recurrence. Eur J Dermatol 2008;18:91-2.
84. Cohen DJ, Scherschun L. Case reports: Practical experience with efalizumab in hand and foot psoriasis. J Drugs Dermatol 2007;6:1224-30.
85. Zip C. Treatment of hand and foot psoriasis with emphasis on efalizumab. Skin Therapy Lett 2007;12:7-9.
86. Ko JM, Gottlieb AB, Kerbleski J F. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 2009;20:100-8.
87. Rivard J, Janiga J, Lim HW. Tacrolimus ointment 0.1% alone and in combination with medium-dose UVA1 in the treatment of palmar or plantar psoriasis. J Drugs Dermatol 2006;5:505-10.
88. V'lckova-Laskoska MT, Caca-Biljanovska NG, Laskoski DS, Kamberova SJ. Palmoplantar pustulosis treated with itraconazole: A single, active-arm pilot study. Dermatol Ther 2009;22:85-9.
89. Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007;57:1-27.
90. de Berker D. Management of psoriatic nail disease. Semin Cutan Med Surg 2009;28:39-43.
91. de Jong EM, Seegers BA, Gulinck MK, Boezeman JB, van de Kerkhof PC. Psoriasis of the nails associated with disability in a large number of patients: Results of a recent interview with 1, 728 patients. Dermatology 1996;193:300-3.
92. Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:206-12.
93. Cassell SE, Bieber JD, Rich P, Tutuncu ZN, Lee SJ, Kalunian KC, et al. The modified Nail Psoriasis Severity Index: Validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007;34:123-9.
94. Kaçar N, Ergin S, Erdoan BS. The comparison of Nail Psoriasis Severity Index with a less time-consuming qualitative system. J Eur Acad Dermatol Venereol 2008;22:219-22.
95. Cassell S, Kavanaugh A F. Therapies for psoriatic nail disease. A systematic review. J Rheumatol 2006;33:1452-6.
96. Murdan S. Enhancing the nail permeability of topically applied drugs. Expert Opin Drug Deliv 2008;5:1267-82.
97. Rigopoulos D, Gregoriou S, Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: A double-blind study. Acta Derm Venereol 2007;87:167-8.
98. Sánchez Regaña M, Martín Ezquerra G, Umbert Millet P, Llambí Mateos F. Treatment of nail psoriasis with 8% clobetasol nail lacquer: Positive experience in 10 patients. J Eur Acad Dermatol Venereol 2005;19:573-7.
99. Grover C, Bansal S, Nanda S, Reddy BS. Efficacy of triamcinolone acetonide in various acquired nail dystrophies. J Dermatol 2005;32:963-8.
100. de Berker DA, Lawrence CM. A simplified protocol of steroid injection for psoriatic nail dystrophy. Br J Dermatol 1998;138:90-5.
101. Peachey RD, Pye RJ, Harman RR. The treatment of psoriatic nail dystrophy with intradermal steroid injections. Br J Dermatol 1976;95:75-8.
102. Bleeker JJ. Intradermal triamcinolone acetonide treatment of psoriatic nail dystrophy with Port-o-Jet. Br J Dermatol 1975;92:479.
103. Bedi TR. Intradermal triamcinolone treatment of psoriatic onychodystrophy. Dermatologica 1977;155:24-7.
104. Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis 2001;68:355-8.
105. Bianchi L, Soda R, Diluvio L, Chimenti S. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study. Br J Dermatol 2003;149:207-9.
106. Diluvio L, Campione E, Paternò EJ, Mordenti C, El Hachem M, Chimenti S. Childhood nail psoriasis: A useful treatment with tazarotene 0.05%. Pediatr Dermatol 2007;24:332-3.
107. Zakeri M, Valikhani M, Mortazavi H, Barzegari M. Topical calcipotriol therapy in nail psoriasis: A study of 24 cases. Dermatol Online J 2005;11:5.
108. Tosti A, Piraccini BM, Cameli N, Kokely F, Plozzer C, Cannata GE, et al. Calcipotriol ointment in nail psoriasis: A controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998;139:655-9.
109. Rigopoulos D, Ioannides D, Prastitis N, Katsambas A. Nail psoriasis: A combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol 2002;82:140.
110. Tzung TY, Chen CY, Yang CY, Lo PY, Chen YH. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol 2008;88:279-80.
111. Cannavò SP, Guarneri F, Vaccaro M, Borgia F, Guarneri B. Treatment of psoriatic nails with topical cyclosporin: A prospective, randomized placebo-controlled study. Dermatology 2003;206:153-6.
112. Sánchez Regaña M, Márquez Balbás G, Umbert Millet P. Nail psoriasis: A combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment. J Eur Acad Dermatol Venereol 2008;22:963-9.
113. Rados J, Dobrić I, Pasić A, Lipozencić J, Ledić-Drvar D, Stajminger G. Normalization in the appearance of severly damaged psoriatic nails using soft x-rays. A case report. Acta Dermato venerol Croat 2007;15:27-32.
114. Brazzelli V, Martinoli S, Prestinari F, Borroni G. An impressive therapeutic result of nail psoriasis to acitretin. J Eur Acad Dermatol Venereol 2004;18:229-30.
115. Tosti A, Ricotti C, Romanelli P, Cameli N, Piraccini BM. Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009;145:269-71.
116. Syuto T, Abe M, Ishibuchi H, Ishikawa O. Successful treatment of psoriatic nails with low-dose cyclosporine administration. Eur J Dermatol 2007;17:248-9.
117. Feliciani C, Zampetti A, Forleo P Cerritelli L, Amerio P Proietto G, et al. Nail psoriasis: Combined therapy with systemic cyclosporin and topical calcipotriol. J Cutan Med Surg 2004;8:122-5.
118. Vlachou C, Berth-Jones J. Nail psoriasis improvement in a patient treated with fumaric acid esters. J Dermatolog Treat 2007;18:175-7.
119. Szepietowski JC, Salomon J. Do fungi play a role in psoriatic nails? Mycoses 2007;50:437-42.
120. Noiles K, Vender R. Nail psoriasis and biologics. J Cutan Med Surg 2009;13:1-5.
121. Körver JE, Langewouters AM, Van De Kerkhof PC, Pasch MC. Therapeutic effects of a 12-week course of alefacept on nail psoriasis. J Eur Acad Dermatol Venereol 2006;20:1252-5.
122. Lamerson C, Stevens G, Sax K. Treatment of nail psoriasis with efalizumab: a preliminary study. Cutis 2008;82:217-20.